US 9493564
CD86 antagonist multi-target binding proteins
granted A61KA61K2039/505A61K39/00
Quick answer
US patent 9493564 (CD86 antagonist multi-target binding proteins) held by Aptevo Research and Development LLC expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aptevo Research and Development LLC
- Grant date
- Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K2039/505, A61K39/00, A61K39/39558, A61P